Regulus Therapeutics Inc. (RGLS) is a publicly traded company in the Unknown sector. Across all available filings, 36 corporate insiders have executed 276 transactions totaling $150.4M, demonstrating a bearish sentiment with -$15.5M in net insider flow. The most recent transaction on Jul 25, 2024 involved a purchase of 4,000 shares valued at $7.3K.
No significant insider buying has been recorded for RGLS in the recent period.
No significant insider selling has been recorded for RGLS in the recent period.
Based on recent SEC filings, insider sentiment for RGLS is bearish with an Insider Alignment Score of 45/100 and a net flow of -$15.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Regulus Therapeutics Inc. (RGLS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 36 insiders are actively trading RGLS stock, having executed 276 transactions in the past 90 days. The most active insider is Ab Astrazeneca (Executive), who has made 1 transactions totaling $34.0M.
Get notified when executives and directors at RGLS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 25, 2024 | J. Collier Kathryn | Executive | Purchase | 4,000 | $1.82 | $7.3K | |
| Mar 14, 2024 | Papadopoulos Stelios | Executive | Award | 250,000 | $1.60 | $400.0K | |
| Jan 18, 2024 | P. Hagan Joseph | Executive | Sale | 14,580 | $1.19 | $17.4K | |
| Jan 18, 2024 | Ray Aker Christopher | Executive | Sale | 5,468 | $1.19 | $6.5K | |
| Jan 18, 2024 | Calsada Crispina | Executive | Sale | 5,468 | $1.19 | $6.5K | |
| Jan 12, 2024 | Ray Aker Christopher | Executive | Award | 11,250 | $N/A | $0 | |
| Jan 12, 2024 | Calsada Crispina | Executive | Award | 11,250 | $N/A | $0 | |
| Jan 12, 2024 | P. Hagan Joseph | Executive | Award | 30,000 | $N/A | $0 | |
| Apr 13, 2023 | Papadopoulos Stelios | Executive | Award | 222,198 | $0.90 | $200.0K | |
| Mar 1, 2022 | Drygin Denis | Executive | Purchase | 76,686 | $0.23 | $17.6K | |
| Feb 4, 2022 | Drygin Denis | Executive | Purchase | 23,314 | $0.23 | $5.4K | |
| Jan 26, 2022 | P. Hagan Joseph | Executive | Purchase | 100,000 | $0.22 | $22.0K | |
| Nov 30, 2021 | Papadopoulos Stelios | Executive | Award | 2,222,222 | $0.36 | $800.0K | Large |
| May 17, 2021 | Ray Aker Christopher | Executive | Sale | 860 | $0.89 | $765 | |
| May 17, 2021 | P. Hagan Joseph | Executive | Sale | 4,186 | $0.89 | $3.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 147 | $83.0M | 53.7% |
Purchase(P) | 53 | $67.4M | 43.6% |
Award(A) | 34 | $3.5M | 2.3% |
Exercise(M) | 31 | $534.7K | 0.3% |
Conversion(C) | 9 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Insider activity at Regulus Therapeutics Inc. shows mixed signals across all time. While $67.4M in purchases indicates some executive confidence,$83.0M in sales balances the picture, resulting in a modest net flow of -$15.5M.36 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Ab Astrazeneca, has transacted $34.0M during this period.